UGT2B17 as a predictor of response to neoadjuvant therapy in patients with HER2-positive and hormone receptor-negative breast cancer (Machine-translation by Google Translate, not legally binding)

• Main Authors: MOLINA PINELO, Sonia, DOMINGUEZ CEJUDO, María Angeles, GIL TORRALVO, Ana, SALVADOR BOFILL, Francisco Javier, GARRIGOS VACAS, Carmen
• Format: Patent
• Language: English; Spanish
• Published: 23.07.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to the in vitro use of UGT2B17 expression levels to predict or predict the response to neoadjuvant therapy in the treatment of cancer in patients with HER2-positive and hormone receptor-negative breast cancer. In vitro methods are developed to obtain useful data and to predict the response to neoadjuvant therapy in this group of patients, as well as kits to carry out the methods of the invention. (Machine-translation by Google Translate, not legally binding) La presente invención refiere al uso in vitro de los niveles de expresión UGT2B17 predecir o pronosticar la respuesta a la terapia neoadyuvante en el tratamiento del cáncer en pacientes con cáncer mama HER2 positivo y con receptores hormonales negativos. Se desarrollan métodos in vitro para la obtención de datos útiles y para el pronóstico de la respuesta a la terapia neoadyuvante en este grupo de pacientes, así como kits para llevar a cabo los métodos de la invención.